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Multiple Sclerosis (MS) is a global disease with an increasing prevalence during the
last years. Although it has been known since the mid-19th century, heterogeneity
makes it a disease hard to understand. On the road to finding a possible cause for the
onset of MS, many fingers pointed to Epstein-Barr virus (EBV), a viral agent that
infects more than 90% of the population.
EBV establishes lifelong latent infections within B-cells, triggering latency
transcription programs.
The immune response involves the expression of immediate early, early, and late-
stage genes. Natural killer (NK) cells are the initial line of the innate defense and are
abundant in EBV infections. The adaptive immunity is carried by CD8+ T-cells,
although bursts of CD4+ T-cell reactivity can be detected.
Inability to control infection may lead to the development of EBV-related diseases,
including multiple sclerosis.
• Describe the immune mechanisms during EBV infection and in MS patients.
• Explain the development of the autoimmune response.
• Analyse the hypotheses on why an EBV-infected patient may develop MS.
• Mention the existing immunotherapies and upcoming treatments.
• MS is a very heterogeneous disease whose causes are difficult to determine since many environmental and genetic factors are involved.
• EBV infection is a probable disease trigger, but no hypothesis has been confirmed. However, the most accepted one is Pender’s hypothesis on infected autoreactive B-cells.
• The main immune event during EBV infection is the CD8+ T-cell response against lytic epitopes.
• In MS patients, the immune response shows evidence of an impaired attempt to control viral infection.
• There is no ultimate cure for MS, but B-cell depletion therapies have proven successful.
How the path of research will evolve is mostly uncertain, but it is clear that causative agents must be deciphered to progress. Further research is needed in many fields surrounding MS,
and it will not be until these fields are more known that a cure will be developed.
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EPSTEIN-BARR VIRUS MULTIPLE SCLEROSIS
CONCLUSIONS
IMMUNOTHERAPIES
Treatment is used to control inflammatory activity, prevent relapses, and avoid accumulation of disability. Non-symptomatic MS, Relapsing-remitting MS and Secondary
progressive MS patients can be treated with IFNβ, a drug that inhibits infectivity, stimulates T-cell responses and diminishes the memory B-cell compartment. Monoclonal
antibodies are also used in patients to decrease inflammation and block disease progression.
Therapies directed against EBV include:
B-cell depletion therapies Antiviral drugs Vaccination
PROPOSED HYPOTHESES
MS might be a consequence of the immune system
trying to control EBV infection. The exaggerated
response provokes the unveiling of hidden
autoantigens.
Human endogenous retrovirus-W expression has
been detected in active lesions as well as multiple
sclerosis retrovirus titres. EBV infection predisposes
to the presence of HERV-W.
EBV-infected autoreactive B-cells
proliferate and migrate to the brain
where they produce autoantibodies.
Cross-reactive CD4+ T-cells arrive in
the CNS, causing organ damage and
autoimmune disease.
A cross-recognition event (Figure 2)
allows the activation of autoreactive
cells because of structural similarity.
3%-4% of EBNA1 specific CD4+ T-cells
react against myelin-derived peptides.
MOLECULAR MIMICRY PENDER’S HYPOTHESIS
MISTAKEN SELF BYSTANDER DAMAGE INTERACTION WITH HERVs
αβ-Crystallin is a limited-expression protein in
lymphocytes and oligodendrocytes. EBV infection
triggers its expression, and the immune system
mounts a response against it.
MS is a chronic autoimmune demyelinating
disease characterized by inflammatory lesions,
axonal degeneration, gliosis and blood-brain barrier
breakdown. It is consequence of environmental and
genetic factors and is classified into four subtypes.
The immune response plays a huge part in its
development, contributing to neuroinflammation,
myelin damage, and white matter development.
Figure 2: T-cell recognizing a B-cell epitope and an EBV epitope, triggering a cross recognition event.
Created with BioRender.com
Figure 3: Depiction of Pender’s hypothesis on infected autoreactive B-cells. The arrival of infected B-cells to the CNS triggers organ damage.
Adapted from [4]. Created with BioRender.com
Figure 4: Rituximab antibodies attacking the
CD20 antigen present in EBV-infected B-cells.
Created with BioRender.com
Figure 5: Administration of Valacyclovir, which blocks the DNA
polymerase on EBV-lytically infected cells.
Created with BioRender.com
Figure 6: Prophylactic vaccination with anti-gp350 antibodies that will
attack glycoprotein350present on the membrane of EBV.
Created with BioRender.com
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Figure 1: Pathogenesis of multiple sclerosis in the CNS.
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